IL1B and gastric cancer: Studies have demonstrated that astragaloside IV induces anti-inflammatory effects in gastric tissues by suppressing the expression of inflammatory cytokines, such as TNF-α and IL-1β [42], and restrains epithelial-mesenchymal transitions by inhibiting the PI3K/AKT/NF- kappa B pathway in gastric cancer cells [43].